Menu Search
Equities

Clover Corporation Ltd

UWA:BER

Clover Corporation Ltd

Actions
  • Price (EUR)0.302
  • Today's Change0.002 / 0.67%
  • Shares traded-1.00
  • 1 Year change-57.46%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 07:08 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Clover Corporation Limited is focused on technology, new product development and commercialization. The principal activities of the Company are the refining and sale of natural oils, the production of encapsulated powders and the research and product development of functional food and infant nutrition ingredients. The Company’s microencapsulation technology enables nutritional oils, such as tuna, fish, algal and fungal oils, to be added to infant formula, foods, and beverages. Its technologies protect those sensitive oils from oxidation, allowing them to be incorporated into a range of applications. The Company, through its subsidiary, Nu-Mega Ingredients Pty Limited (Nu-Mega), supplies refined Omega-3 oils and a range of other encapsulated ingredients for use in infant formula, nutraceuticals, pharmaceuticals, and sports nutrition markets. Nu-Mega’s Driphorm range of microencapsulated powders enables the addition of Hi-DHA tuna and/or algal oils to a broad spectrum of products.

  • Revenue in AUD (TTM)62.77m
  • Net income in AUD1.92m
  • Incorporated1988
  • Employees56.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.